Clinical Laboratory Improvement Advisory Committee (CLIAC), 82299 [2011-33388]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 76, Number 251 (Friday, December 30, 2011)]
[Notices]
[Page 82299]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-33388]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee (CLIAC)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following meeting of the aforementioned 
committee:

    Dates: Times and Dates: 8:30 a.m.-5 p.m., February 14, 2012. 
8:30 a.m.-12:30 p.m., February 15, 2012.
    Place: Marriott Atlanta Century Center, 2000 Century Boulevard 
NE., Atlanta, Georgia 30345.
    Online Registration Required: All CLIAC attendees are required 
to register for the meeting online at least 5 business days in 
advance for U.S. citizens and at least 10 business days in advance 
for international registrants. Register at https://wwwn.cdc.gov/cliac/default.aspx by scrolling down and clicking the appropriate 
link under ``Meeting Registration'' (either U.S. Citizen 
Registration or Non-U.S. Citizen Registration) and completing all 
forms according to the instructions given. Please complete all the 
required fields before submitting your registration and submit no 
later than February 7, 2012 for U.S. registrants and January 31, 
2012 for international registrants.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This Committee is charged with providing scientific and 
technical advice and guidance to the Secretary, Department of Health 
and Human Services; the Assistant Secretary for Health; the 
Director, CDC; the Commissioner, Food and Drug Administration (FDA); 
and the Administrator, Centers for Medicare and Medicaid Services 
(CMS), regarding the need for, and the nature of, revisions to the 
standards under which clinical laboratories are regulated; the 
impact on medical and laboratory practice of proposed revisions to 
the standards; and the modification of the standards to accommodate 
technological advances.
    Matters To Be Discussed: The agenda will include agency updates 
from the CDC, the Centers for Medicare & Medicaid Services (CMS), 
and the Food and Drug Administration (FDA). Additional agenda items 
include presentations and discussions addressing the following: 
activities of the Coordinating Council on the Clinical Laboratory 
Workforce; laboratory communication and electronic health records, 
integration of laboratory services into healthcare models; automated 
cytology workload limits; and emerging challenges in digital 
pathology.
    Agenda items are subject to change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible. Oral Comments: In general, each 
individual or group requesting to make an oral presentation will be 
limited to a total time of five minutes (unless otherwise 
indicated). Speakers must also submit their comments in writing for 
inclusion in the meeting's Summary Report. To assure adequate time 
is scheduled for public comments, individuals or groups planning to 
make an oral presentation should, when possible, notify the contact 
person below at least one week prior to the meeting date. Written 
Comments: For individuals or groups unable to attend the meeting, 
CLIAC accepts written comments until the date of the meeting (unless 
otherwise stated). However, it is requested that comments be 
submitted at least one week prior to the meeting date so that the 
comments may be made available to the Committee for their 
consideration and public distribution. Written comments, one hard 
copy with original signature, should be provided to the contact 
person below. Written comments will be included in the meeting's 
Summary Report.
    Availability of Meeting Materials: To support the green 
initiatives of the federal government, the CLIAC meeting materials 
will be made available to the public in electronic format (PDF) on 
the Internet instead of by printed copy. Refer to the CLIAC Web site 
on the day of the meeting for materials. https://wwwn.cdc.gov/cliac/cliac_meeting_all_documents.aspx.
    An Internet connection, power source and limited hard copies may 
be available at the meeting location, but cannot be guaranteed.
    Contact Person for Additional Information: Nancy Anderson, 
Chief, Laboratory Practice Standards Branch, Division of Laboratory 
Science and Standards, Laboratory Science, Policy and Practice 
Program Office, Office of Surveillance, Epidemiology and Laboratory 
Services, Centers for Disease Control and Prevention, 1600 Clifton 
Road, NE., Mailstop F-11, Atlanta, Georgia 30333; telephone (404) 
498-2741; fax (404) 498-2219; or via email at 
Nancy.Anderson@cdc.hhs.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining 
to announcements of meetings and other committee management 
activities for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

    Dated: December 22, 2011.
Ronald Ergle,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 2011-33388 Filed 12-29-11; 8:45 am]
BILLING CODE 4163-18-P